芬纳西泮 | 51753-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 芬纳西泮
• 中文别名: 5-(2-氯苯基)-7-溴-1,4-苯并二氮杂卓-2-酮；7-溴-5-(2-氯苯基)-1,3-二氢-3H-1,4-苯并二氮杂卓-2-酮；7-溴-5-(2-氯苯基)-1,3-二氢-2H-1,4-苯并二氮杂卓-2-酮；5-(2-氯苯基)-7-溴-1,4-苯并二氮杂卓
• 英文名称: phenazepam
• 英文别名: 5-(2'-chloro-phenyl)-7-bromo-1,3-dihydro-2H-1,4-benzodiazepin-2-one；7-bromo-5-(2'-chlorophenyl)-1,2-dihydro-3H-1,4-benzodiazepin-2-one；7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one；7-bromo-5-(o-chlorophenyl)-1,2-dihydro-3H-1,4-benzodiazepin-2-one；fenazepam；7-bromo-5-(2-chloro-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one；7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 51753-57-2
• 化学式: C₁₅H₁₀BrClN₂O
• 分子量: 349.614
• InChiKey: CGMJQQJSWIRRRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

制备方法与用途

制备方法

该药物属于精神病类药物，药性相对较强。

用途简介

暂无相关信息。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	2-amino-N-[4-bromo-2-(2-chlorobenzoyl)phenyl]acetamide	——	C15H12BrClN2O2	367.62

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	7-bromo-5-(2-chloro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	37638-89-4	C16H12BrClN2O	363.641
  3-羟基芬纳西泮	7-bromo-5-(o-chlorophenyl)-3-hydroxy-1,2-dihydro-3H-1,4-benzodiazepin-2-one	70030-11-4	C15H10BrClN2O2	365.614
  1,3-二氢-5-(2-氯苯基)-2H-1,4-苯并二氮杂卓-2-酮	5-<2-Chlor-phenyl>-3H-1,4-benzodiazepin-2(1H)-on	3022-68-2	C15H11ClN2O	270.718
  (5E)-7-溴-5-(2-氯-6-氧代-1-环己-2,4-二烯亚基)-3,4-二氢-1H-1,4-苯并二氮杂卓-2-酮	7-Bromo-5-(2-chloro-6-hydroxy-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one	74077-25-1	C15H10BrClN2O2	365.614
  7-溴-5-(2-氯苯基)-1,3-二氢-1,4-苯并二氮杂-2-硫酮	7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-thione	87213-49-8	C15H10BrClN2S	365.681
  1,3-二氢-5-苯基-1,4-苯并二氮杂卓-2-酮	2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one	2898-08-0	C15H12N2O	236.273

反应信息

• 作为反应物：
  描述：

  芬纳西泮 在 盐酸 作用下， 反应 0.5h， 生成 2-氨基-5-溴-2’-氯二苯甲酮
  参考文献：
  名称：

  Metabolism of phenazepam in the rat organism

  摘要：

  DOI：

  10.1007/bf00777451
• 作为产物：
  描述：

  2-氨基-5-溴-2’-氯二苯甲酮 在 一水合肼 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 8.5h， 生成 芬纳西泮
  参考文献：
  名称：

  Synthesis of two 1-substituted 8-bromo-6-(2-chlorophenyl)-4H-s-triazolo[4,3-a]-1,4-benzodiazepines

  摘要：

  2-氨基-5-溴-2'-氯苯基酮（VII）通过与邻二甲酰氯反应形成邻二甲酰亚胺衍生物（VIII），该衍生物通过肼解反应转化为7-溴-5-(2-氯苯基)-1,3-二氢-1,4-苯并二氮杂环己酮（II）。在吡啶中和五硫化二磷反应得到巯内酰胺（IX），它与醋酸肼和甲硫基乙酸肼在沸腾的1-丁醇中反应，形成了标题化合物V和VI。化合物V在小鼠的抗惊厥、中枢抑制和不协调活性药理试验中具有很强的效果，而化合物VI略弱。

  DOI：

  10.1135/cccc19831477

文献信息

• [EN] TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES DU SPECTRE AUTISTIQUE, DE TROUBLES OBSESSIVO-COMPULSIFS ET DE TROUBLES DE L'ANXIÉTÉ
  申请人：RUGEN HOLDINGS CAYMAN LTD

  公开号：WO2018098128A1

  公开（公告）日：2018-05-31

  Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

  揭示了通过给予特定NR2B亚单位选择性NMDA（N-甲基-D-天冬氨酸）拮抗剂来治疗NMDA受体介导的疾病的方法。NMDA受体介导的疾病包括自闭症谱系障碍、强迫症和焦虑症。
• [EN] TREATMENT OF ANXIETY DISORDERS AND AUTISM SPECTRUM DISORDERS<br/>[FR] TRAITEMENT DES TROUBLES DE L'ANXIÉTÉ ET DES TROUBLES DU SPECTRE AUTISTIQUE
  申请人：RUGEN HOLDINGS CAYMAN LTD

  公开号：WO2016049048A1

  公开（公告）日：2016-03-31

  Disclosed are methods for treating autism spectrum disorders and/or anxiety disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. Anxiety disorders include agoraphobia (with or without panic disorder), generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD).

  本文披露了通过给予特定NR2B亚单位选择性NMDA（N-甲基-D-天冬氨酸）拮抗剂来治疗自闭症谱系障碍和/或焦虑障碍的方法。焦虑障碍包括广场恐惧症（伴有或不伴有惊恐障碍）、广泛性焦虑障碍（GAD）、社交焦虑障碍（SAD）、惊恐障碍（PD）、创伤后应激障碍（PTSD）和强迫症（OCD）。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2015066344A1

  公开（公告）日：2015-05-07

  Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

  提供了5-HT2C受体激动剂。还提供了用于体重管理、诱导饱腹感、减少食物摄入量、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。还提供了包含选择性5-HT2C受体激动剂的组合物，可选地与辅助剂结合，以及用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少使用烟草制品的个体戒除或减少使用烟草制品；帮助戒烟并预防相关体重增加；通过个体尝试戒烟来控制与戒烟相关的体重增加；通过个体尝试戒烟来减少与戒烟相关的体重增加；治疗尼古丁依赖、成瘾和/或戒断的个体尝试治疗尼古丁依赖、成瘾和/或戒断；或减少个体尝试戒除尼古丁使用的复发可能性，包括给予选择性5-HT2C受体激动剂，可选地与辅助剂结合。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DES RÉCEPTEURS 5-HT2C ET COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2016176177A1

  公开（公告）日：2016-11-03

  Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent.

  在某些实施例中提供了本文中的化合物。在某些实施例中还提供了用于体重管理、诱发饱腹感、减少食物摄入、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理赌博、奖赏缺乏综合征、性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构紊乱和慢波睡眠障碍）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。在某些实施例中还提供了包含本文中的化合物的组合物，可选择地与辅助剂结合，并且提供了用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少吸烟产品的使用；帮助戒烟并预防相关体重增加；通过个体试图戒烟来控制与戒烟相关的体重增加；通过个体试图戒烟来减少与戒烟相关的体重增加；治疗个体试图治疗尼古丁依赖、成瘾和/或戒断的尼古丁依赖、成瘾和/或戒断；或减少个体试图停止尼古丁使用的复发尼古丁使用的可能性，包括给予本文中的化合物，可选择地与辅助剂结合。